NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy.

Slides:



Advertisements
Similar presentations
Oncologists Views about the Treatments and Care Associated with Advanced varian Cancer Jenkins V 1, Banerjee S 2, Ledermann J 3, Gore M 2, Catt S 1, Monson.
Advertisements

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Research Study Designs
Rare Tumour Working Group. Active Trials GOG 187 Phase 2 paclitaxel as 2 nd line therapy for ovarian stromal tumours-almost complete GOG239-Phase 2 AZD6244(MEK.
1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.
Consequences of Treatment for Rectal Cancer Gillian Knowles, Rachel Haigh, Catriona McLean, Hamish Phillips, Malcolm Dunlop, Farhat Din.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Patient-Reported Outcomes: Introducion and Overview Pythia Nieuwkerk, PhD Department of Medical Psychology Academic Medical Center, Amsterdam.
Rehabilitative care approach in a specialist palliative day care centre: a study of patient’s perspectives Author: C.A. Belchamber October 2003.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,
Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant ovarian cancer Michael Friedlander Phyllis Butow, Martin.
Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
OVARIAN CANCER New NICE guidelines and the research behind them Journal Club 20/5/11 Natalie Brown and Matthew Parkes.
Early treatment of relapsed ovarian cancer based on CA125 level alone
, START UP MEETING FOR STAGE 2. Response Rates in Phase 3 Trials Chemotherapy Response rates % Liposomal doxorubicin Gemcitabine 5-9 Gemcitabine.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy.
Chemotherapy Audit  Audit of patients who died within three months of their last dose of chemotherapy at Airedale General Hospital  The records of 50.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.
Hospice Basics: Palliative Care vs. Curative Care.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.
Phase II in Second Line NSCLC DefinitionPhase II: BI 6727 vs. BI 6727+pemetrexed vs. pemetrexed in second line advanced NSCLC Early stopping.
Presented By: Mohammed Al-Issa. Objectives of the Study To assess the degree of satisfaction among dialysis patients in their dialytic therapy. To assess.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer Taroh.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Hungarian Pancreatic Study Group – Magyar Hasnyálmirigy Munkacsoport Gábor Lakatos 09 november th Conference of the Hungarian & 2 nd Conference.
Impact on Quality of Life of Adding Cetuximab to Irinotecan in Patients Who Have Failed Prior Oxaliplatin-Based Therapy: Results From the EPIC Trial Cathy.
Health-related quality of life in patients with oesophageal- and gastric cancer Lovisa Backemar, MD Surgical Care Sciences Department of Molecular Medicine.
Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.
Quality of Life and Functional Results Following Pelvic Exenteration Erin Kennedy September 19, 2015.
Quality of life and its health- relations. Definitions.
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
until tumour progression until tumour progression
Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Vivek Nama UHBT. Surgical staging: Tumour grade Myometrial invasion Lymphovascular space involvement Cervical stromal invasion Spread to regional lymphnodes.
Janet H. Van Cleave PhD, RN1 Brian Egleston PhD2
Cetuximab plus FOLFIRI 1 st -line in patients (pts) with metastatic colorectal cancer (mCRC): A quality of life (QoL) analysis of the CRYSTAL trial G.
Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.
CoRPS Center of Research on Psychology in Somatic diseases Multiple myeloma survivors experience a low quality of life and many disease-specific complaints:
Experiences and Attitudes of Patients With Terminal Cancer and Their Family Caregivers Toward the Disclosure of Terminal Illness Young Ho Yun, Yong Chol.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial Patricia.
1 RTOG 1115 Health Related Quality of Life and Comparative Effectiveness Deborah Watkins Bruner, RN, PhD, FAAN.
Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”
1 LUX-Lung 3 clinical trial ECOG=Eastern Cooperative Oncology Group. Sequist LV et al. J Clin Oncol. 2013;31(27): Treatment-naïve Advanced NSCLC.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Claudia Marchetti Pierluigi Benedetti Panici
LUX-Lung 3 clinical trial
Long Term Effects of Surgery and Radiotherapy for Colorectal Cancer on Bowel Function and Quality of Life Gillian Knowles, Rachel Haigh, Catriona McLean,
Lessons Learned Through HBD: The Regulator’s View - US FDA
Results: Patient details Results: QoL
Charles D. Gerson, Mary-Joan Gerson 
Untch M et al. Proc SABCS 2010;Abstract P
(NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG)
IMagyn050 YO39523/GOG-3015/ENGOT-ov39 Recruitment Update
Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.
Richard J Gralla, MD, Frank Griesinger, MD, PhD 
Evaluating the Totality of Evidence
Living with Ovarian Cancer: How Palliative Care Can Help
Presentation transcript:

NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy in women with platinum refractory/ resistant ovarian cancer ANZGOG – 0701

NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Study Background The aim is to develop a method to measure the benefit of chemotherapy, which takes into account BOTH subjective and objective responses Document time to symptom progression as an additional endpoint as well as symptom benefit Better insight into patterns of care and reasons for treatment with platinum resistant or refractory ovarian cancer Develop a prognostic index that better defines outcomes and test in a separate group

NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Objective Stage 1: To determine the symptoms and aspects of HRQL that are rated most severe, troublesome in patients and identify best instruments to use in stage 2 Stage 2: To determine the proportion of women benefiting from palliative chemotherapy as defined by a clinically significant improvement in HRQL scores and improvement of symptoms and time to symptom progression.

NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre REGISTERREGISTER Target Population >18yrs platinum resistant/ refractory epithelial ovarian cancer ECOG 0-3 Able to commence treatment within 2wks of registration Ability to complete QoL forms independently During Trial Stage1 Complete QoL questionnaires at each cycle 20 subjects will participate in additional QoL telephone interviews Stage2 Determine the optimal QoL forms from Stage1 Longer follow-up Prognostic data collected at baseline Data Collection 4 Treatment cycles or Disease progression Proposed longer follow-up for Stage 2 Study Schema

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Current status Fourteen sites open to recruitment Twelve in Australia Two in Canada A further nine Australian sites are currently awaiting final ethics approval Total recruitment Australia 20 Canada

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Baseline Demographics Symptom control/palliation + rising CA125 + radiological progression28 Rising CA125 + radiological progression9 Symptom control/palliation + rising CA1256 Symptom Control + radiological evidence1 Radiological Evidence only1 Rising CA125 only1 N = 46 Reason for treatment at enrolment

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Baseline Demographics cont’d Major symptoms reported at baseline: 1. Pain 2. Fatigue 3. Abdominal Bloating ECOG 0 = 17 (N = 45 - missing data for one patient) 1 = 26 2 = 2 3 = 0

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Stage 1 QoL Questionnaires 1.Symptom Representation Questionnaire 2.FACT-O (includes FOSI) 3.EORTC QLQ-C30 4.EORTC QLQ-OV28 5.Patient Data Form 6.Expected and Perceived Benefit Scale 7.HAD Scale (Baseline & End of Treatment only) 8.Herth Hope Index (Baseline & End of Treatment only)

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Results: Top 10 Symptoms of the ‘Three Most Noticed Symptoms in the last week’ at baseline RankSymptom No. who nominated this symptom in her Top 3 (n=31) 1Fatigue17 2Pain - general11 3Abdominal bloating10 4Sleep disturbance9 5Nausea and vomiting8 6Appetite7 7Shortness of breath6 8Bowel disturbances (including constipation)6 9Pain - abdominal5 10Urinary problems3

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Coverage of Top 10 symptoms by candidate questionnaires Symptom SRQPt DATAFACT-OFOSIQLQ-C30QLQ-OV28 Fatigue Pain - general Abdominal bloating Sleep disturbance Nausea and vomiting Appetite Shortness of breath Bowel disturbances Pain - abdominal Urinary problems # items covering Top Total # items in q’aire %50%83%23%75%40%32%

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Decisions Retain modified Pt DATA Form – Ovarian to measure key symptoms Enhance coverage of the Top 10 Allow measurement of both current status and change Modifications by developer and OSBS investigators  OSBS Recent Status Form (after each cycle) OSBS Change Form(after every 2 nd cycle) Develop a separate Side Effects Form for net clinical benefit Retain FACT-O (including FOSI) to measure QOL FACT-O Has fewer items: 39 (incl. 8 for FOSI) vs. 58 in the QLQ- C30/Ov28 Provides summary scores: overall QOL, Trial Outcome Index, FOSI Overall QOL based on all items QLQ-C30 22 sub scales Duplication of single-item symptoms with Pt DATA Form Global QOL based on 2 items

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Prognostic Model variables No. of lines of therapy Performance status Volume of disease Sites of disease CA125 velocity LDH; Hb; Albumin; Platelets Inflammatory markers Grade; histological subtype

ANZGOG AGM, Noosa 2 April 2009 NHMRC Clinical Trials Centre Platinum Resistant Ovarian Cancer Hypothetical Risk Groups PFS